Co-Founder @AganithaAI | Transforming BioPharma R&D with Computational Biology/Chemistry and AI | Building multi-disciplinary teams | Author
Joined July 2022
- Tweets27
- Following225
- Followers31
- Likes130
Looking forward to speaking today at the Claude Community event in Hyderabad on:
🎤 Beyond Automation: Architecting the Agentic Enterprise
I'll be sharing implementation lessons from human–agent workflows for scientific R&D at @AganithaAI
luma.com/cccl.hyd2
Looking forward to the session at AIPM in @iitmadras today. I'm planning to show in action, Aganitha Igniva™ agents for: hypothesis validation, target elucidation, protocol generation, MD results analysis, listening to voices of patients, HCPs and KOLs, and much more.
🚀Real-World Applications of #AgenticAI Accelerating #Biopharma R&D and Care
👉 Join us at AIPM-India 2025 in @iitmadras to see in action, Igniva™ AI agents, built on 5+ years of global biopharma R&D collaborations by 100+ researchers at Aganitha
ALT Aganitha Presents Beyond the hype: Real-world application of Agentic AI accelerating R&D and Care Prasad Chodavarapu Aganitha.ai 2025 Symposium on Artificial Intelligence and Pharmaceutical Medicine (AIPM-India) At 10:30 am on Sep 11, 2025 (Thursday) TTJ AUDITORIUM, IIT Madras
I’ve seen firsthand how many painful iterations multi-disciplinary teams go through to decode the biology hidden in #SingleCell #Omics data.
There has to be a faster way — one built for better collaboration, powered by #AI and #LLMs.
#DISTILL is our shot at doing this right.
🔬 DISTILLing Complex Biology in the #SingleCell & #AgenticAI Era
Why should single cell #omics analysis still take months, even in 2025?
In this video, Ananya Jana explains the core challenges single cell researchers face today and how DISTLL™ accelerates journey to insights.
If we’re to distribute the fruits of modern #science to all of humanity, we must find ways to scale access to expertise. #AI can be a powerful enabler on this path — augmenting human insight, accelerating development, and broadening accessibility.
📢 Personalized #GeneTherapy is here. #AI can help widen access.
A few days after KJ Muldoon was born, he was diagnosed with a rare genetic disorder. Doctors told his family:
“Your son is very sick. The best place in the world to be when your child is sick is next door.”
First in a series of #Igniva #AgenticAI demos we'll be posting. This one recaps the analysis in a blog by @doctorveera on a genetic variant in NOTCH3 that's associated with Stroke in South Asian populations.
🧬 Excited to share a glimpse into the future of #Biopharma R&D with Aganitha #Igniva #AgenticAI Demo
Igniva is our suite of research agents that integrate #LLMs with scientific data, tools & workflows to tackle complex problems like variant effect analysis.
Reflecting on #virtualcell: Given that no cell is an island, what's the chance of inferring biology looking at just a single cell's transcriptome?
Quoting arxiv.org/abs/2503.03485: "After all, we do not have healthy or diseased annotations for individual cells."
#singlecell #AI
Glad to see multi-cell, multi-modal model attempted.
C2S-scale extends Cell2Sentences (C2S), a previous #virtualcell model, to 27B parameters, training on a 1B token Multi-modal dataset with a context length of 8192 (this needs to increase too).
biorxiv.org/content/10.1101/…
Talk to us at #PMWC25 to see demos and know more first hand.
aganitha.ai/pmwc25/
Aganitha Launches Igniva™: A Suite of AI Agents for Therapeutic Design and Research
Igniva™ #AgenticAI analyzes & reasons over biological, chemical & clinical datasets, knowledge bases, and computational & AI models, with human experts in the loop.
aganitha.ai/company/news-and…
In the panel discussion at #BiologicsWorkshop2025 in Goa last week, discussing #AI for #Bioprocess. Consensus was that AI adoption for meeting operational needs is proving easier than adoption for process optimisation given the regulated nature of bioprocesses.
Loved the interactions at #BiologicsWorkshop2025 in Goa last week. I shared three case studies illustrating convergence of #AI and #DeepScience in the modeling and optimization of synthesis processes for mAb, mRNA and Gene therapies.
Prasad Chodavarapu retweeted
📢 Join us at #PMWC25 to talk about AI in BioPharma R&D
Vikram Duvvoori (@VikramDu), CEO of Aganitha.ai, will be presenting case studies showing how #GenAl & in silico modeling are mining insights from deep science to accelerate #BioPharma R&D. See you there.
ALT Beyond the Hype: Al Case Studies Accelerating Biopharma R&D Speaker: Vikram Duvvoori CEO & Co-Founder Aganitha Al Feb 5, 11:00 am, Showcase Track SI Precision Medicine World Conference (PMWC - 2025) Dates: 5 - 7 February 2025 Venue: Santa Clara Convention Center Booth: #B722
In the age of CRISPR, Gen AI & population-scale health data, BioPharma R&D is drinking from a firehose and understandably, getting drenched in the process without quenching the thirst for approved therapies. DBTIPS™ is our attempt to make this challenge more tractable.
🧬 Announcing Aganitha Disease Biomarker & Target Insights Platform & Services (#DBTIPS™)
Details at
aganitha.ai/solutions/target…
Summary in 🧵👇
#DrugDiscovery #Biomarkers #PrecisionMedicine #AI #Biopharma
Representing @AganithaAI at @Capgemini LSH @nasscomai @IFCCI1 hosted #AIEHyderabad event on "Accelerating drug discovery and development", answering questions on application of #GenerativeAI and progress in #PrecisionMedicine
Prasad Chodavarapu retweeted
Delighted to share results from our Molecular Dynamics (MD) simulations investigating why Siponimod, a FDA-approved drug for relapsing forms of Multiple Sclerosis, activates its GPCR target, S1PR1 but not S1PR2, an off-target from the same family.
🧵👇
biorxiv.org/content/10.1101/…
🚀 @AganithaAI ARC™ Framework combines LLM capabilities with #biopharma expertise, offering customized tools and services. See attached 🧵for details and demos.
🔬 Unlock the Power of #LLM in #Biopharma with Aganitha’s ARC™ Framework
1. Auto-analyze #Omics datasets
2. Discover novel drug targets & biomarkers
3. Generate & review regulatory submissions & contracts
4. Reduce hallucinations
See aganitha.ai/services/large-l…
Demos in 🧵
Prasad Chodavarapu retweeted
Excited to announce Aganitha’s collaboration with @ccmb_csir to apply Generative AI solutions for designing novel therapeutics and research antibodies addressing needs in multiple disease areas.
More details at aganitha.ai/company/news-and…
Absolutely! AI is everywhere in science now. AI is helping us mine insights from large datasets produced by high-throughput experiments. We are in a Deep Science + Deep Tech era. We explain with a few examples in a recent blog at
aganitha.ai/ai-everywhere/
The 'Science in the Age of AI' report explores the opportunities and challenges of machine learning and large-language models as transformative tools for 21st century research. Read the full report now: royalsociety.org/news-resour…
2023 was an amazing year for us at #Aganitha with #GenerativeAI models in #Biology / #Chemistry and #LLMs expanding the power of in silico solutions we provide for Biopharma R&D acceleration. Highlights in attached newsletter.
linkedin.com/pulse/happy-new…
Loved Day 1 at the #IITBBiopharmaSummit2023 so amazingly put together by Prof. @Pramod_Wangikar and team. Looking forward to my presentation today morning.
Complexity of Biology and vastness of Chemistry are leading us to high-throughput & deep science; and, hashtag#AI is helping us absorb and leverage the insights produced.
We need uninhibited cross-disciplinary collaboration now more than ever to unleash the virtuous loop between deep science & deep tech. Will share in my talk today, some of our work at aganitha.ai in this super-exciting space.